FTB-918 is a first-in-class, dual-targeting antibody fusion engineered to simultaneously deplete pathogenic T cells and neutralize IL-17A, addressing both a cellular driver and a key inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results